High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules.

Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat Commun (2012) 1.70

Increasing the Content of High-Content Screening: An Overview. J Biomol Screen (2014) 1.36

Adapting human pluripotent stem cells to high-throughput and high-content screening. Nat Protoc (2012) 0.97

Small molecule screening in human induced pluripotent stem cell-derived terminal cell types. J Biol Chem (2013) 0.93

A high-content platform to characterise human induced pluripotent stem cell lines. Methods (2015) 0.86

Potential for pharmacological manipulation of human embryonic stem cells. Br J Pharmacol (2013) 0.85

Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. Cell Death Dis (2016) 0.81

Human pluripotent stem cells on artificial microenvironments: a high content perspective. Front Pharmacol (2014) 0.81

Sialyl-lactotetra, a novel cell surface marker of undifferentiated human pluripotent stem cells. J Biol Chem (2014) 0.81

Structural complexity of non-acid glycosphingolipids in human embryonic stem cells grown under feeder-free conditions. J Biol Chem (2013) 0.80

Small molecule screening with laser cytometry can be used to identify pro-survival molecules in human embryonic stem cells. PLoS One (2013) 0.76

Real-time monitoring of specific oxygen uptake rates of embryonic stem cells in a microfluidic cell culture device. Biotechnol J (2016) 0.75

DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science (2005) 5.20

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood (2006) 4.41

Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature (2008) 4.09

Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97

Behavioral phenotypes of Disc1 missense mutations in mice. Neuron (2007) 3.68

Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (2002) 3.46

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J (2003) 3.43

The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol (2002) 2.99

Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat Neurosci (2010) 2.90

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood (2007) 2.68

International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62

Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res (2004) 2.58

beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A (2003) 2.43

Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41

Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29

Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol (2010) 2.11

The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur J Immunol (2006) 2.09

Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08

The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function. Mol Pharmacol (2007) 1.92

Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91

RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem (2005) 1.89

Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev (2010) 1.89

IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res (2008) 1.87

Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol (2008) 1.85

Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol (2002) 1.85

Sleep deprivation impairs cAMP signalling in the hippocampus. Nature (2009) 1.83

G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82

PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J Cell Biol (2006) 1.81

International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev (2008) 1.80

beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem (2004) 1.75

A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem J (2008) 1.73

Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett (2005) 1.66

Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci (2007) 1.64

Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol (2010) 1.63

Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochem J (2008) 1.62

Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ Res (2008) 1.62

G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation (2005) 1.57

Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci Signal (2010) 1.54

DISC1-dependent switch from progenitor proliferation to migration in the developing cortex. Nature (2011) 1.53

Ectodysplasin has a dual role in ectodermal organogenesis: inhibition of Bmp activity and induction of Shh expression. Development (2007) 1.53

Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol Cell (2011) 1.52

Sterile inflammation associated with transradial catheterization and hydrophilic sheaths. Catheter Cardiovasc Interv (2003) 1.52

Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol (2006) 1.50

BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods (2007) 1.48

Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem J (2006) 1.46

External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer (2008) 1.45

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood (2006) 1.43

Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3. Mol Pharmacol (2007) 1.43

Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem (2006) 1.43

Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J (2002) 1.43

EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. Proc Natl Acad Sci U S A (2008) 1.43

Laparoscopic radical prostatectomy: initial 70 cases at a U.S. university medical center. Urology (2002) 1.41

The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res (2003) 1.38

The Cellient automated cell block system is useful in the differential diagnosis of atypical glandular cells in Papanicolaou tests. Cancer Cytopathol (2013) 1.38

Creation of engineered human embryonic stem cell lines using phiC31 integrase. Stem Cells (2007) 1.35

A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr Biol (2010) 1.34

Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase. J Biol Chem (2009) 1.33

Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol (2005) 1.33

Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem (2011) 1.33

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem Pharmacol (2010) 1.33

The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med (2012) 1.32

Punish the parent not the progeny. Blood (2004) 1.32

Facilitated expansion of human embryonic stem cells by single-cell enzymatic dissociation. Stem Cells (2007) 1.32

p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J Cell Biol (2007) 1.30

In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal (2005) 1.27

Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem (2003) 1.27

The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J Biol Chem (2005) 1.27

Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc (2011) 1.26

Derivation of a xeno-free human embryonic stem cell line. Stem Cells (2006) 1.26

Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol (2009) 1.26

The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol (2008) 1.26

DNA variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular diagnostics. Hum Mutat (2013) 1.25

Eczema herpeticum: a dermatologic emergency. Dermatol Nurs (2002) 1.25

An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia. Hum Mutat (2012) 1.25

Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice. J Clin Invest (2007) 1.23

Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. Biochem J (2010) 1.22

Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol (2005) 1.22

Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J Biol Chem (2008) 1.21

Techniques: promiscuous Galpha proteins in basic research and drug discovery. Trends Pharmacol Sci (2005) 1.21

Real-time monitoring of redox changes in the mammalian endoplasmic reticulum. J Cell Sci (2011) 1.21

The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem (2009) 1.21

Toward specifying pervasive developmental disorder-not otherwise specified. Autism Res (2011) 1.20

Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and beta1 integrin and for tumor cell proliferation and migration. J Biol Chem (2008) 1.19

The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol (2013) 1.18

Analysis of group differences in processing speed: Brinley plots, Q-Q plots, and other conspiracies. Psychon Bull Rev (2003) 1.18

Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells (2012) 1.18

Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J Biol Chem (2010) 1.18

IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol (2006) 1.17

When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol (2010) 1.17

The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem (2003) 1.17